KN

Kinnate Biopharma IncNASDAQ KNTE Stock Report

Last reporting period 30 Sep, 2023

Updated —

Last price

Market cap $B

0.125

Micro

Exchange

XNAS - Nasdaq

KNTE Stock Analysis

KN

Uncovered

Kinnate Biopharma Inc is uncovered by Eyestock quantitative analysis.

Market cap $B

0.125

Dividend yield

Shares outstanding

46.57 B

Kinnate Biopharma, Inc. operates as a biopharmaceutical company engaged in the research and development of Kinnate Discovery Engine that targets genomic drivers of cancer. The company is headquartered in San Diego, California and currently employs 84 full-time employees. The company went IPO on 2020-12-03. Its products candidate include KIN-2787, KIN-3248 and KIN004. The KIN-2787 is a small molecule kinase inhibitor targeting specific classes of BRAF kinase alterations that characterize subsets of lung cancer, melanoma and other solid tumors. The firm has initiated a Phase I clinical trial for KIN-2787 (KN-8701). KIN-3248 is a small-molecule kinase inhibitor targeting cancer-associated alterations in FGFR2 and FGFR3 genes. KIN-3248 address the initial alteration and clinically-observed and predicted mutations in FGFR2 fusion gene-positive intrahepatic cholangiocarcinoma and FGFR3-altered ulcerative colitis. The company is also developing a CDK12 inhibitor candidate to target the treatment of ovarian carcinoma, metastatic castration-resistant prostate cancer and triple-negative breast cancer.

View Section: Eyestock Rating